89bio Inc . (NASDAQ:ETNB), a clinical-stage biopharmaceutical company valued at $937 million, is navigating the complex landscape of metabolic and liver diseases with its lead candidate ...

89bio Inc . (NASDAQ:ETNB), a clinical-stage biopharmaceutical company valued at $937 million, is navigating the complex landscape of metabolic and liver diseases with its lead candidate, pegozafermin.

SAN FRANCISCO, Nov. 29, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on ...

89bio, Inc. ETNB is a clinical-stage biopharmaceutical company. The Zacks Consensus Estimate for its current year earnings has been revised 38.8% downward over the last 60 days.

Other approaches that are in development include fibroblast growth factor (FGF) mimetics such as FGF21-targeting candidates ...

Check the time stamp on this data. Updated AI-Generated Signals for 89bio Inc. (ETNB) available here: ETNB. Type a few ...

After Donald Trump suggested he might take over Greenland by force, the consensus among the island’s population appears to be bewilderment and anxiety. By Jeffrey Gettleman and Maya Tekeli ...

After Donald Trump suggested he might take over Greenland by force, the consensus among the island’s population appears to be bewilderment and anxiety. By Jeffrey Gettleman and Maya Tekeli The ...